Voyager Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report. Voyager is a preclinical biotechnology company developing AAV gene therapies and other treatments for neurological diseases, including through its TRACER capsid platform. All active product candidates were in preclinical development at year-end.
Financial performance and position
| Metric | FY2022 / Dec. 31, 2022 | FY2021 / Dec. 31, 2021 |
|---|---|---|
| Collaboration revenue | $40.9 million | $37.4 million |
| Research and development expense | $60.8 million | $73.8 million |
| General and administrative expense | $31.0 million | $37.2 million |
| Operating loss | $50.8 million | $73.6 million |
| Net loss | $46.4 million | $71.2 million |
| Operating cash flow | $(12.5) million | $(53.5) million |
| Cash, cash equivalents and marketable securities | $118.8 million | $132.5 million |
| Current assets / current liabilities | $124.5 million / $72.6 million | $136.7 million / $51.0 million |
FY2022 collaboration revenue was not product sales: the company has not generated product revenue. Pfizer contributed $40.0 million of recognized revenue, principally following exercise of a license option and expiration of another material right; Neurocrine collaboration revenue was $0.9 million. Net loss improved by $24.8 million year over year as operating expenses fell by $19.3 million and other income increased.
FY2022 operating and net margins were approximately -124% and -113%, respectively, based on reported revenue. The filing reports no conventional borrowings; liabilities primarily include deferred collaboration revenue, lease liabilities and other operating obligations. Deferred revenue totaled $65.8 million at year-end. The current ratio was approximately 1.7x.
Material changes and notable items
- Research and development expense declined $13.0 million and general and administrative expense declined $6.3 million, reflecting the prior restructuring, lower headcount, reduced program activity and facility savings.
- Operating cash use fell to $12.5 million, partly because deferred revenue increased, including the $54.0 million Novartis upfront payment received in 2022. This cash-flow figure should not be read as the company’s underlying operating burn without considering working-capital and contract-liability movements.
- Voyager recognized a $2.5 million gain after terminating a Cambridge lease in June 2022, without termination penalties. It also paid a $5.0 million Touchlight technology-access fee, recorded as R&D expense.
- Cash, cash equivalents and marketable securities declined from $132.5 million to $118.8 million. FY2022 net loss was $46.4 million; accumulated deficit reached $393.5 million.
Outlook, collaborations and principal risks
- Management estimated that year-end 2022 liquidity, together with the Neurocrine upfront payment received in February 2023 and expected collaboration cost reimbursements, would fund planned operating expenses and capital expenditures into 2025. This is a management estimate dependent on operating plans and partner funding; the company expects to need additional capital over time.
- In February 2023, Neurocrine paid approximately $136 million upfront and approximately $39 million for 4,395,588 newly issued shares. The collaboration covers GBA1 gene therapy and three discovery programs, with substantial potential development and commercial milestones and royalties. These contingent amounts are not guaranteed revenue.
- Novartis exercised options for two capsids effective March 1, 2023; Voyager expected a $25 million option-exercise payment in the first half of 2023, plus potential future milestones and royalties. Novartis did not license one other target, and associated rights reverted to Voyager.
- Voyager expected to file INDs for its wholly owned anti-tau Alzheimer’s program and SOD1 ALS program in 2024. VY-TAU01 was selected as the anti-tau lead in January 2023; a SOD1 lead candidate was expected in the first half of 2023. Timelines and outcomes remain uncertain.
- Key risks include the early, preclinical stage of the pipeline; uncertain safety, efficacy, regulatory requirements and development costs for gene therapies; dependence on collaboration partners and contract manufacturers; competition; intellectual-property exposure; and the need for future financing. The filing also identifies constrained availability of non-human primates for preclinical studies and reliance on a sole manufacturer for certain vectors.
- Voyager terminated its 75 Sidney Street lease and reported no material pending legal proceedings at December 31, 2022. The auditor issued an unmodified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting.
Investor verification points
- Confirm subsequent-period receipt and accounting treatment of the Neurocrine upfront payment, equity proceeds and Novartis option payment, including the effect of share issuance and dilution.
- Review the cash runway assumptions and reconcile operating cash use with collaboration reimbursements, deferred revenue and planned R&D spending.
- Track progress toward SOD1 and anti-tau IND filings planned for 2024, and assess whether preclinical evidence supports those timelines.
- Monitor Neurocrine and other partner decisions, program funding, option rights, termination provisions and the contingent nature of milestones and royalties.
- Assess manufacturing capacity, single-source vector dependence, non-human-primate supply, gene-therapy safety and regulatory risks, and potential intellectual-property obligations, including Touchlight royalties.